Cargando…
Using a “systems therapeutic for physiological renormalization” approach to vaccine development. Covid-19 as an example
Current vaccines for Covid-19 have failed to prevent the disease from spreading and have allowed more transmissible and virulent variants to form through mutations and recombinations as they replicate during the massive spread of the virions. Here I suggest using a “systems therapeutic” vaccine and...
Autor principal: | Maguire, Greg |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9196663/ https://www.ncbi.nlm.nih.gov/pubmed/35240929 http://dx.doi.org/10.1080/21645515.2022.2043105 |
Ejemplares similares
-
Physiological renormalization using systems therapeutics
por: Maguire, Greg
Publicado: (2019) -
COVID-19 vaccine hesitancy: misinformation and perceptions of vaccine safety
por: Kricorian, Katherine, et al.
Publicado: (2021) -
Immunomodulatory and therapeutic implications of vitamin D in the management of COVID-19
por: Dhawan, Manish, et al.
Publicado: (2022) -
Status of COVID-19 vaccination around South Asia
por: Hayat, Mahnoor, et al.
Publicado: (2022) -
A recombinant Mycobacterium smegmatis-based surface display system for developing the T cell-based COVID-19 vaccine
por: Wen, Ziyu, et al.
Publicado: (2023)